DnaJ heat shock protein family (Hsp40) member C9Genealiases: HDJC9 · JDD1 · SB73
Q-omics provides the consensus-scored DNAJC9 profile across patient tissues and cancer cell-line models. DNAJC9 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DNAJC9 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, DNAJC9 protein abundance shows 26,082 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where DNAJC9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DNAJC9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DNAJC9 survival associations across molecular data types. DNAJC9 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DNAJC9 RNA expression–survival associations across cancer types. High DNAJC9 expression shows unfavorable associations in ACC, MESO, UVM, LIHC, LUAD and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DNAJC9 RNA expression.
This table summarizes DNAJC9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DNAJC9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DNAJC9 shows higher tumor expression in HNSC, COAD, KIRP, LUAD, LIHC and LUSC. The HNSC box plot shows higher DNAJC9 RNA expression in tumor versus normal tissue (log2 FC = +1.029, t-test p < 0.001).
This table shows molecular features associated with DNAJC9 in patient tissues and cancer cell lines. In patient samples, DNAJC9 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, DNAJC9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
